Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

Firibastat in Treatment-resistant Hypertension

ClinicalTrials.gov ID: NCT04277884

Public ClinicalTrials.gov record NCT04277884. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jun 26, 2026, 12:01 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Double-blind, Placebo-controlled, Efficacy and Safety Study of Firibastat (QGC001) Administered Orally, Twice Daily, Over 12 Weeks in Difficult-to-treat/Resistant Hypertensive Subjects

Study identification

NCT ID
NCT04277884
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Quantum Genomics SA
Industry
Enrollment
515 participants

Conditions and interventions

Conditions

Interventions

  • Firibastat Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 24, 2020
Primary completion
Aug 29, 2022
Completion
Sep 19, 2022
Last update posted
Oct 19, 2022

2020 – 2022

United States locations

U.S. sites
15
U.S. states
8
U.S. cities
14
Facility City State ZIP Site status
Central Alabama Research Birmingham Alabama 35209-8401
Marvel Clinical Research Huntington Beach California 92647
Orange County Research Center Tustin California 92780
Jacksonville Center for Clinical Research Jacksonville Florida 32216
Progressive Medical Research Port Orange Florida 32127
Cardiovascular Center of Sarasota Sarasota Florida 34239
Apex Medical Research Chicago Illinois 60607
Cedar Crosse Research Center Chicago Illinois 60607
ClinEdge - Chear Center The Bronx New York 10455
Sterling Research Group - Cincinnati / Mount Auburn Cincinnati Ohio 45219
Insearch - Punzi Medical Center Carrollton Texas 75006
ClinEdge - Dayton Clinical Research Dayton Texas 45406-5144
Juno Research - Corporate Office Houston Texas 77040
Insearch - R&H Clinical Research Katy Texas 77450
Manassas Clinical Research Center Manassas Virginia 20110

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04277884, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 19, 2022 · Synced Jun 26, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04277884 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →